3. Johnson & Johnson  $19.1B ▲37.4%  

Global revenue: $36.4B (6th); up 20.9%
Top brands: Remicade ($4.5B); Xarelto ($2.1B); Olysio ($2.0B); Stelara ($1.5B); Zytiga ($971M)
Promotional spend: $1.0B (5th); 5.2% of rev.
R&D spend: $8.5B (3rd); up 0.6%; 23.4% of rev.
Planned launches: guselkumab (imm.); daratumumab (onc.)
Patent expirations: Prezista (2016); Zytiga (2016); Remicade (2018)

Behemoth Johnson & Johnson has a presence in just about every category that has the market’s attention, including cancer drugs (Imbruvica, which has garnered four indications since its 2013 approval for mantle cell lymphoma), hepatitis-C treatments (Olysio) and blood drugs (Xarelto). J&J sat out 2014’s wave of tax-inversion efforts and M&A activity, but it was scooped by AbbVie’s $21-billion bid to buy Imbruvica partner Pharmacyclics. In its wake, J&J has pursued a lower-key purchase of XO1 Limited, which is developing anti-anticoagulants that can counter offerings like the aforementioned Xarelto, which are shadowed by bleeding concerns. Of course, given its presence in just about every category, J&J is sensitive to industry tremors and could soon find itself in a turf war between branded biologics, like Remicade, and the biosimilars that are expected to chip away at the branded market. While CEO Alex Gorsky said he expects Europe’s Remicade biosimilar will have an impact on 2015 sales, at least one industry watcher expects US sales of the drug to notch single-digit yearly growth until its expected 2018 patent expiration.

Click here to return to main story.